Lexaria begins animal study on next-generation GLP-1 drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar pushes higher, yen sinks to 40-year low
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
June 9, 2026 9:25 AM EDTRetatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH
KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECHTM performance as well as potentially stake new... More
